Oakmark Funds, advised by Harris Associates, released its “Oakmark Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund underperformed its benchmark, the S&P 500 Index, but outperformed the benchmark since inception. The largest contributors to performance were financials and energy, at the sector level, while health care and consumer staples detracted. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025. ...

I have covered several companies in the shipping industry over the years, but BW LPG Limited (NYSE: BWLP ) never managed to draw my attention. But its case appears quite interesting to me today because very large gas carrier ratesI cover stocks that I usually own or that I like to research. I also believe in the future of Bitcoin. Follow me for intricate ideas and (hopefully) market-beating returns :) .Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies men ...

Key Takeaways NEOG's first-quarter EPS missed by 20% as revenues came in above consensus at $209.2 million.Neogen's Q1 Food Safety fell 4.6%, Animal Safety down 0.8%, Genomics returned to mid-single-digit growth.Neogen expects fiscal 2026 revenues of $820-$840M, adjusted EBITDA $165-$175M and CapEx of around $50M.Neogen Corporation (NEOG) reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of 4 cents, which missed the Zacks Consensus Estimate by 20%. The bottom line fell 42.9% from the year ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter, the fund underperformed its benchmark, the S&P 500 Index, but outperformed the benchmark since inception. The largest contributors to performance were financials and energy, at the sector level, while health care and consumer staples detracted. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025. ...

PLTR Technical AnalysisPalantir looks like it’s going to open somewhat flat, but it was trying to recover during the trading session on Thursday. So, it does make a certain amount of sense that some momentum might enter the market here. If we can break above the crucial $190 level, Palantir has a real shot at taking off to the upside and perhaps going to the $200 level. A pullback from here could open up the possibility of a test of the 50-day EMA, but as things stand right now, I don’t think any pullback e ...

Now, candidates from private sector can apply for the post of Managing Director in State Bank of India and for Managing Director-cum-Chief Executive Officer in any of 11 public sector banks. The Cabinet Committee on Appointment (ACC) has approved the changes in the guidelines.According to new set of guidelines, made public by Financial Services Department, out of four positions of Managing Director in SBI, one position has been opened for private sector candidates and persons working in public sector financ ...

*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet. Information in Investor's Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, o ...

By Christy Santhosh (Reuters) -Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing competition from generic drugs. The deal expands Bristol Myers Squibb's CAR T-cell immunotherapy portfolio with Orbital's lead experimental candidate, OTX-201, which is designed to target autoimmune diseases. This marks the company's first major acquisition of the year, as it shift ...

Key Takeaways ZBH expands its foot & ankle trauma portfolio with Gorilla Pilon Fusion and Phantom TTC launches.ZBH reinforces commitment to surgical innovation, targeting complex pilon fractures and hindfoot injuries.ZBH shares dipped post-announcement, but the launches may drive renewed momentum in stock performance.Zimmer Biomet Holdings (ZBH) , together with its subsidiary Paragon 28, has announced the full commercial launch of two solutions for complex foot and ankle trauma. The Gorilla Pilon Fusion Pla ...

Some tickers are covered more than others on the site, so with The Undercovered Dozen our Editors highlight twelve actionable investment ideas on tickers with less coverage. These ideas can range from "boring" large caps to promising up-and-coming small caps. Specifically, the inclusion criteria for "undercovered" include: market cap greater than $100 million, more than 800 symbol page views in the last 90 days on Seeking Alpha, and fewer than two articles published in the past 30 days. Follow this account ...